Patents Examined by Richard Hutson
-
Patent number: 9862938Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.Type: GrantFiled: May 7, 2014Date of Patent: January 9, 2018Assignee: Life Technologies CorporationInventors: Michael D. Smith, Robert Jason Potter, Gulshan Dhariwal, Gary F. Gerard, Kim Rosenthal, Jun E. Lee
-
Patent number: 9856463Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.Type: GrantFiled: January 15, 2016Date of Patent: January 2, 2018Assignee: Roche Molecular Systems, Inc.Inventors: Fred Reichert, Keith Bauer, Thomas W. Myers
-
Patent number: 9840698Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.Type: GrantFiled: April 25, 2016Date of Patent: December 12, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Fred Reichert, Keith Bauer, Thomas W. Myers
-
Patent number: 9834761Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.Type: GrantFiled: February 9, 2016Date of Patent: December 5, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Fred Reichert, Keith Bauer, Thomas W. Myers
-
Patent number: 9803180Abstract: The present invention relates to isolated polypeptides that are derived from wildtype Bacillus subtilis S-Adenosylmethionine (SAM) synthase or from a biologically active fragment thereof, wherein said isolated polypeptides comprise an amino acid sequence that, in relation to the amino acid sequence of said wildtype Bacillus subtilis SAM synthase or of the biologically active fragment thereof, comprises at least one amino acid substitution, selected from the group consisting of amino acid substitutions at positions I317 and I105. The present invention further relates to respective isolated nucleic acids, vectors, host cells, uses and methods for the production of SAM derivatives.Type: GrantFiled: September 4, 2014Date of Patent: October 31, 2017Assignee: LEIBNIZ-INSTITUT FÜR PFLANZENBIOCHEMIE STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Martin Dippe, Wolfgang Brandt, Ludger A. Wessjohann, Hannes Rost, Andrea Porzel
-
Patent number: 9796965Abstract: The present invention generally relates to detection of a target nucleic acid in standard PCR, real-time PCR, RT PCR, and real-time RT PCR. One aspect of the invention provides mutant DNA polymerase enzymes that are resistant to PCR inhibitors, such as dye, blood, and soil. Another aspect of the invention provides for methods of real-time PCR assays using mutant DNA polymerase enzymes resistant to PCR inhibitors with samples containing dye, blood, and/or soil. Another aspect of the invention provides for methods of standard PCR assays using mutant DNA polymerase enzymes resistant to PCR inhibitors with samples containing blood and/or soil.Type: GrantFiled: June 23, 2015Date of Patent: October 24, 2017Assignee: DNA Polymerase Technology, Inc.Inventors: Milko Kermekchiev, Lyubka Kirilova, Zhian Zhang
-
Patent number: 9771565Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.Type: GrantFiled: August 23, 2010Date of Patent: September 26, 2017Assignee: Life Technologies CorporationInventors: Jun Lee, Robert Jason Potter
-
Patent number: 9771608Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor.Type: GrantFiled: June 27, 2016Date of Patent: September 26, 2017Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Takashi Ueda
-
Patent number: 9765377Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor.Type: GrantFiled: June 27, 2016Date of Patent: September 19, 2017Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Takashi Ueda
-
Patent number: 9765312Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.Type: GrantFiled: February 5, 2016Date of Patent: September 19, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Fred Reichert, Keith Bauer, Thomas W. Myers
-
Patent number: 9764008Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.Type: GrantFiled: May 9, 2013Date of Patent: September 19, 2017Assignee: Yeda Research and Development Co. Ltd.Inventors: Irit Sagi, Eitan Wong, Ran Afik
-
Patent number: 9765311Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.Type: GrantFiled: January 15, 2016Date of Patent: September 19, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Fred Reichert, Keith Bauer, Thomas W. Myers
-
Patent number: 9765315Abstract: The present invention provides nucleotide sequences of Macrophomina phaseolina (“M. phaseolina”) that encodes proteins/enzymes with cellulolytic activity, including a cellulase activity, a endoglucanase, a cellobiohydrolase, a ?-glucosidase, a a-glucosidase, a xylanase, a mannanse, a ?-xylosidase, a a-xylosidase, a galactosidase, an arabinofuranosidase, a a-fucosidases, a ?-galactanase, an unsaturated ?-glucuronyl hydrolase and/or oligomerase activity. Vectors, expression constructs and host cells comprising and/or consisting of the nucleotide sequences of the enzyme genes are also provided. The invention further provides methods for producing the enzymes and methods for modifying the enzymes in order to improve their desirable characteristics. The enzymes of the invention can be used in a variety of, but not limited to, pharmaceutical, agricultural, food and feed processing, biofuel, energy efficiency and industrial contexts.Type: GrantFiled: August 15, 2013Date of Patent: September 19, 2017Assignee: Bangladesh Jute Research InstituteInventors: Maqsudul Alam, Mohammed S. Islam, Mohammed M. Hossen, Mohammed S. Haque, Mohammed M. Alam
-
Patent number: 9758771Abstract: Provided are a beta prime subunit mutant of RNA polymerase, a microorganism of the Corynebacterium genus including a polynucleotide coding the same, and a method for producing L-lysine by culturing the same.Type: GrantFiled: June 24, 2014Date of Patent: September 12, 2017Assignee: CJ CHEILJEDANG CORPORATIONInventors: Sang Hee Park, Jun Ok Moon, Kwang Ho Lee
-
Patent number: 9758804Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor.Type: GrantFiled: June 27, 2016Date of Patent: September 12, 2017Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Takashi Ueda
-
Patent number: 9752171Abstract: The present invention provides recombinant nucleic acid constructs comprising a xylose isomerase polynucleotide, a recombinant fungal host cell comprising a recombinant xylose isomerase polynucleotide, and related methods.Type: GrantFiled: September 30, 2015Date of Patent: September 5, 2017Assignee: Codexis, Inc.Inventors: Ezhilkani Subbian, Xiyun Zhang, Benjamin N. Mijts, Catherine M. Cho
-
Patent number: 9745557Abstract: The invention relates to the nucleotide and amino acid sequences, and to the activity and use, of the luciferases LuAL, Lu164, Lu16, Lu39, Lu45, Lu52 and Lu22.Type: GrantFiled: May 15, 2015Date of Patent: August 29, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Stefan Golz, Bernd Kalthof, Svetlana Markova, Ludmila Frank, Eugene Vysotski
-
Patent number: 9738876Abstract: Disclosed are mutant DNA polymerases having improved extension rates relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.Type: GrantFiled: January 20, 2015Date of Patent: August 22, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Keith A. Bauer, Ellen Fiss, David Harrow Gelfand, Edward S. Smith, Shawn Suko, Thomas W. Myers
-
Patent number: 9732364Abstract: The present invention relates to use of inducible promoters in the production of methionine by fermentation. The present invention concerns a method for the production of methionine, its precursors or derivatives in a fermentative process comprising the following steps: culturing a modified microorganism in an appropriate culture medium comprising a source of carbon, a source of sulphur and a source of nitrogen, and recovering methionine and/or its derivatives from the culture medium, wherein in said modified microorganism, the expression of at least one gene involved in methionine production is under the control, direct or indirect, of a heterologous inducible promoter. The invention also concerned the modified microorganism used in the method.Type: GrantFiled: December 13, 2010Date of Patent: August 15, 2017Assignee: EVONIK DEGUSSA GMBHInventors: Rainer Figge, Perrine Vasseur
-
Patent number: 9719073Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing. Such properties can include enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased thermostability, increased accuracy, increased speed, increased readlength, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.Type: GrantFiled: March 9, 2015Date of Patent: August 1, 2017Assignee: Pacific Biosciences of California, Inc.Inventors: Robin Emig, Insil Park, Lei Jia, Molly He, Jeremiah Hanes, Harold Lee, Fred Christians, Satwik Kamtekar, Erik Miller